Foghorn Therapeutics Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Flagship Ventures Fund V General Partner LLC, was filed 29 Oct 2020.
Foghorn Therapeutics Inc.: what insiders have been doing
Foghorn Therapeutics Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). In the past year (22 October 2025 to 22 October 2026), 4 filings came from 1 insider.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
With 4 filings in twelve months, the company is quieter than the median of 24 filings across the 3,171 companies we follow on the same exchange. Since 2020, the database holds 3 purchases and 8 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 30.9 m USD and net income of -74.3 m USD.
There has been no open-market purchase by an insider of Foghorn Therapeutics Inc. for at least a year. The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Since the insiders bought
- -21.5%Entry US$15.98 · Close at T+365 US$12.54
- -21.5%Entry US$15.98 · Close at T+365 US$12.54
- -20.7%Entry US$16.00 · Close at T+365 US$12.69
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Foghorn Therapeutics Inc. Buy (bullish), based on 6 analysts. Average price target: US$4.17.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 47,497 shares0Common StockSEC:0001828724-26-000005:0
- 47,497 shares0Common StockSEC:0001828724-26-000005:1
- 59,208 shares0Common StockSEC:0001828724-26-000005:2
- 59,208 shares0Common StockSEC:0001828724-26-000005:3
- 300,000 shares0Common StockSEC:0001562180-25-003257:1
- 300,000 shares0Common StockSEC:0001562180-25-003257:0
- 197,906 shares0Common StockSEC:0001562180-25-003092:1
- 197,906 shares0Common StockSEC:0001562180-25-003092:0
- 35,756 shares@ US$10.0444.2% of flowCommon StockSEC:0001562180-24-006927:1
- 857 shares@ US$3.720.4% of flowCommon StockSEC:0001562180-24-006927:2
- 857 shares@ US$10.171.1% of flowCommon StockSEC:0001562180-24-006927:3
- 35,756 shares@ US$3.7274.8% of flowCommon StockSEC:0001562180-24-006927:0
- 11,574 shares@ US$10.0514.4% of flowCommon StockSEC:0001562180-24-006885:1
- 11,574 shares@ US$3.7224.3% of flowCommon StockSEC:0001562180-24-006885:0
- 400 shares@ US$10.000.5% of flowCommon StockSEC:0001562180-24-006859:1
- 10,272 shares@ US$3.724.7% of flowCommon StockSEC:0001562180-24-006859:2
- 10,272 shares@ US$10.0412.8% of flowCommon StockSEC:0001562180-24-006859:3
- 400 shares@ US$3.720.8% of flowCommon StockSEC:0001562180-24-006859:0
- 20,000 shares@ US$9.5096.0% of flowCommon StockSEC:0001562180-24-006767:0
- 11,000 shares@ US$6.5576100.0% of flowCommon StockSEC:0001562180-24-002591:0
- 311,297 shares@ US$8.2568.9% of flowCommon StockSEC:0001562180-23-006433:1
- 63,000 shares0Common StockSEC:0001562180-23-006432:1
- 311,297 shares@ US$3.72100.0% of flowCommon StockSEC:0001562180-23-006433:0
- 63,000 shares0Common StockSEC:0001562180-23-006432:0
- 300,000 shares0Common StockSEC:0001562180-23-004642:1
25 of 54 declarations
About Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc. (ticker: FHTX) is a U.S.-based biotechnology company listed on the NASDAQ market in the United States. For French-speaking investors, Foghorn fits the profile of a next-generation biotech platform rather than a mature commercial pharma company. It is focused on discovering and developing medicines that target genetically determined dependencies within the chromatin regulatory system, an area of biology linked to how genes are switched on and off. The company was founded in October 2015 and has built its strategy around its proprietary Gene Traffic Control® platform, which is designed to identify, validate, and exploit novel drug targets in disease areas with significant unmet medical need.
Foghorn’s core business is drug discovery and early-to-midstage development, with an emphasis on precision oncology. Its pipeline includes proprietary enzymatic inhibitors, targeted protein degraders, and transcription factor disruptors. Among the most closely watched programs are FHD-909, an oral, selective BRM/SMARCA2 inhibitor, and selective degrader programs targeting CBP, EP300, and ARID1B. The company has also advanced FHD-286, a dual BRG1/BRM-related inhibitor, in specific oncology settings. In other words, Foghorn is not yet a sales-led company; its valuation thesis is driven by the scientific quality of its platform, the progress of its candidates, and the potential for strategic collaborations or clinical milestones.
Read moreShow less
From a competitive standpoint, Foghorn operates in a highly crowded and capital-intensive biotech landscape. Its differentiation lies in the depth of its chromatin biology expertise and the breadth of opportunities that may emerge from one platform. That said, like most development-stage biotech firms, it faces material clinical, regulatory, financing, and execution risks. The opportunity is attractive because the biology is novel and potentially broad, but the path to commercialization remains uncertain.
Geographically, the company’s footprint is centered in the United States, with headquarters in Watertown, Massachusetts, near the Boston/Cambridge life-science cluster. Recent company disclosures in 2026 point to continued pipeline momentum and a strengthened balance sheet following a January 2026 equity financing with a group of leading life-science investors. In March 2026, management also provided a financial update and strategic outlook for 2025 and 2026, highlighting ongoing development priorities across FHD-909, CBP, EP300, and ARID1B. For investors in Europe, Foghorn is best viewed as a high-risk, high-upside NASDAQ-listed biotech story anchored in platform innovation, clinical optionality, and long-dated value creation rather than near-term earnings.
